Albert David Limited (ALBERTDAVD) fundamentals
Albert David Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as ALBERTDAVD (ISIN INE155C01010). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Albert David Limited does
Albert David Limited is an India-based pharmaceutical company. The Company's principal business is manufacturing and trading of pharmaceutical formulations, infusion solutions, herbal dosage forms and bulk drugs by way of domestic sale or export. Its product categories include formulations and bulk drugs. Its product range includes Placentrex range, Anaflam range and BREAZE range. Its formulations include parenteral, oral/enteral, topical agents and vision care. Its parenteral categories include amino acids infusion, anti-microbial, anti-leishmaniasis (kalazar), haemostat (inj), lvp, neurotropic vitamin and placenta extract. The Company's oral/enteral categories include amino acids oral, anthelmintic, anti-microbial, anti-ulcer ants, anti-vertigo, appetite stimulants, anti-tubercular, expectorant / cough syrup, hematinic, haemostat, hepato protective (ayurveda) and hepato protective (others). Its vision care categories include anti glaucoma, anti-infective and NSAID.
Valuation and market data
| Last close | ₹850.00 |
|---|---|
| Market capitalisation | ₹483 crore |
| Enterprise value | ₹495 crore |
| P/E (TTM) | 0.00 |
| Price to book | 1.23 |
| Price to sales (TTM) | 0.74 |
| Book value per share | ₹688.48 |
| Dividend yield | 58.82% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Tue Jun 14 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹341 crore | ₹1 crore | ₹-1 crore | -2.62 |
| Mar 2025 | ₹375 crore | ₹25 crore | ₹17 crore | 30.14 |
| Mar 2024 | ₹420 crore | ₹97 crore | ₹75 crore | 132.15 |
| Mar 2023 | ₹357 crore | ₹51 crore | ₹36 crore | 63.39 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 62.2% |
|---|---|
| Foreign institutions (FII) | 0.6% |
| Mutual funds | 0.0% |
| Other domestic institutions | 1.6% |
| Retail and others | 35.6% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.